Skip to content
homeHOME R&D Major Achievements

Major Achievements

Partners: SpineBiophama, YH14618 - $218,150,000, 2018.7.26 / Partners: Janssen, LECLAZA® (Lazertinib) - $1,255,000,000, 2018.11.5 / Partners: GILEAD, YHC1102, YHC1108 - $785,000,000, 2019.1.17 / Partners: Boehringer Ingelheim, YH25724 - $870,000,000, 2019.7.1 / Partners: Processa Pharmaceuticals, YH12852 - $410,500,000, 2020.8.20

YH14618 LECLAZA®
(Lazertinib)
YHC1102,
YHC1108
YH25724 YH12852
Licensor Spine Biopharma
(US)
Janssen Biotech
(US)
Gilead Sciences
(US)
Boehringer
Ingelheim
(Germany)
Processa
Pharmaceuticals
(US)
Indication Degenerative
Disc Disease
Non small cell lung cancer Nonalcoholic
steatohepatitis
Nonalcoholic
steatohepatitis
Functional GI
motility-related
disorders
Development
stage
Ph 2 clinical study

• Launched in Korea as second-line monotherapy

• Global Ph 3 study as
first-line monotherapy

• Global Ph 3 study as
first-line combination therapy

• Global Ph 1/1b study as
third-line combination therapy

Lead candidate Preclinical Ph 1 clinical study
Key
milestone(s)
in 2021
Entering late-stage
clinical study
in the US

Global clinical studies

Initiation of
preclinical studies
Entering Ph 1
clinical study
in EU
Entering Ph 2
clinical study
in the US